Last week, Republicans in the House of Representatives and in the Senate introduced legislation that would restrict generic and biosimilar developers from challenging patents on reference drugs using the inter partes review (IPR) process.
Last week, Republicans in the House of Representatives and in the Senate introduced legislation that would restrict generic and biosimilar developers from challenging patents on reference drugs using the inter partes review (IPR) process.
The bill, titled the Hatch-Waxman Integrity Act of 2018, was originally proposed by Senator Orrin Hatch, R-Utah, as an amendment to the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act) in June of 2018. In its form introduced this month by Hatch, Representative Bill Flores, R-Texas, and Senator Thom Tillis, R-North Carolina, the proposed legislation would amend the Food, Drug, and Cosmetics Act and the Securities Exchange Act to restrict generic or biosimilar developers from availing themselves of both the IPR and/or post-grant review (PGR) process and litigation pathways provided for under the Hatch-Waxman Act for generics or the Biologics Price Competition and Innovation Act for biosimilars.
According to a summary of the bill provided by Hatch, Congress never intended for the IPR process to “upset” standard litigation procedures, and the new legislation would “close the loophole” created by the IPR process.
The name of Hatch’s new legislation references The Drug Price Competition and Patent Term Restoration Act of 1984, referred to colloquially as “Hatch-Waxman” after Hatch and former Representative Henry Waxman, D-California, who were cosponsors of the 1984 legislation that created the foundation for the US generics market. However, Waxman has been vocal in his criticism of the new bill.
Writing with coauthors Bill Corr and Kristi Martin in The Commonwealth Fund after Hatch first unveiled his plan as an amendment to the CREATES Act, Waxman said that Hatch’s proposal would “delay the ability to challenge and resolve invalid patents for brand-name drugs and thereby also delay development of lower-priced generics.”
Waxman and his coauthors went on to write that “The IPR process is one of several key policy mechanisms for encouraging competition and reducing prices in the pharmaceutical markets. Efforts to undermine this process—such as the proposed Hatch amendment—will likely undermine current efforts to ease the burden of high drug costs on American consumers by allowing brand-name manufacturers to extend monopoly pricing.”
Many in the pharmaceutical industry, however, have met the proposed legislation with support. James C. Greenwood, chief executive officer of the Biotechnology Innovation Organization, said in a statement that the IPR process, which he termed “unforeseen gamesmanship,” has undermined the law’s balance of the need for generics with the need to defend innovation.
“The majority of biotechnology companies are small companies that have no products on the market, and thus their research and development activities are funded through massive amounts of private sector investment over many years, sometimes even decades. Without strong, predictable and enforceable protections for patented inventions, investors will shy away from investing in biotech innovation,” said Greenwood.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).